[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Inagaki H, Kojima H, Kato J, Kojima T, Fujimitsu Y, Matsui T, Miyashita Y, Sakamoto J: [Effective use of combination chemotherapy with paclitaxel and 5-fluorouracil in a case of non-resectable advanced gastric cancer]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1983-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The operative finding was carcinomatous peritonitis in which the primary lesion was considered to be surgically unresectable.
  • After 2 courses of the chemotherapy, the tumor markers were reduced remarkably, ascites had completely disappeared, and abdominal lymph nodes had decreased.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Paclitaxel / administration & dosage. Peritonitis / etiology. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650972.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Sato T, Ohwada A, Miyaji A, Miyazaki R, Suzuki M, Matsumoto T: Immunohistochemistry for the differentiation of peritoneal disseminated carcinoma of unknown origin. Intern Med; 2004 May;43(5):415-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a woman with ascites, hydrothorax, pancreatic tumor, left cystic ovarian tumor, and an elevated serum cancer antigen 125 level.
  • Immunohistochemistry is an adjunct tool to differentiate the primary site of carcinomatous peritonitis.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritonitis / diagnosis. Risk Assessment. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15206556.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


3. Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, Mantovani A: Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol; 2010;2010:547179
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-Associated Macrophages (TAMs) are abundantly present in the stroma of solid tumors and modulate several important biological processes, such as neoangiogenesis, cancer cell proliferation and invasion, and suppression of adaptive immune responses.
  • Myeloid C-type lectin receptors (CLRs) constitute a large family of transmembrane carbohydrate-binding receptors that recognize pathogens as well as endogenous glycoproteins.
  • Components of carcinomatous ascites and purified tumoral mucins (CA125 and TAG-72) bound the MR and induced its internalization.
  • [MeSH-major] Lectins, C-Type / immunology. Macrophages / immunology. Mannose-Binding Lectins / immunology. Mucins / immunology. Ovarian Neoplasms / immunology. Receptors, Cell Surface / immunology
  • [MeSH-minor] Adaptive Immunity / drug effects. Adaptive Immunity / immunology. Antibodies / immunology. Antibodies / pharmacology. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. CA-125 Antigen / genetics. CA-125 Antigen / immunology. CA-125 Antigen / metabolism. Chemokine CCL3 / immunology. Chemokine CCL3 / metabolism. Endocytosis / immunology. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Gene Expression Profiling. Glycoproteins / immunology. Glycoproteins / metabolism. Humans. Immunohistochemistry. Interferon-gamma / pharmacology. Interleukin-10 / immunology. Interleukin-10 / metabolism. Interleukin-10 / pharmacology. Interleukin-12 / immunology. Interleukin-12 / metabolism. Lipopolysaccharides / pharmacology. Membrane Proteins / genetics. Membrane Proteins / immunology. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Rev. 2009 Jul;230(1):22-37 [19594627.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3730-41 [11034378.001]
  • [Cites] Lancet Oncol. 2009 Sep;10(9):877-84 [19656725.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] Exp Hematol. 2009 Dec;37(12):1445-53 [19772890.001]
  • [Cites] Nat Rev Cancer. 2009 Dec;9(12):874-85 [19935676.001]
  • [Cites] Reprod Sci. 2010 Mar;17(3):209-18 [20065301.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Nat Rev Immunol. 2010 Apr;10(4):278-84 [20224568.001]
  • [Cites] Immunobiology. 2009;214(7):554-61 [19162368.001]
  • [Cites] Hepatology. 2010 Jun;51(6):2172-82 [20513002.001]
  • [Cites] J Immunol. 2010 Jul 1;185(1):642-52 [20530259.001]
  • [Cites] Cancer Res. 2010 Jul 15;70(14):5728-39 [20570887.001]
  • [Cites] J Immunol. 2010 Aug 1;185(3):1522-31 [20610655.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):762-7 [10623821.001]
  • [Cites] J Exp Med. 2000 Apr 3;191(7):1117-26 [10748230.001]
  • [Cites] Vaccine. 2000 Jul 15;18(27):3174-84 [10856797.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7477-85 [11390501.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1823-34 [11748283.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):269-76 [11805139.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Annu Rev Immunol. 2002;20:197-216 [11861602.001]
  • [Cites] Science. 2002 Mar 8;295(5561):1898-901 [11884756.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Infect Immun. 2003 Jan;71(1):437-45 [12496194.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):7-17 [12515809.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4671-6 [12907648.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4552-60 [14568928.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6213-21 [14573639.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Annu Rev Immunol. 2004;22:33-54 [15032573.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7341-9 [15187110.001]
  • [Cites] Nat Med. 2004 Aug;10(8):801-5 [15286781.001]
  • [Cites] J Cell Biol. 1982 Feb;92(2):417-24 [6277962.001]
  • [Cites] Adv Exp Med Biol. 1982;155:401-7 [6297268.001]
  • [Cites] Immunol Rev. 1998 Jun;163:19-34 [9700499.001]
  • [Cites] Immunity. 1999 Feb;10(2):137-42 [10072066.001]
  • [Cites] Curr Opin Immunol. 2005 Feb;17(1):18-24 [15653305.001]
  • [Cites] Hum Reprod. 2005 Apr;20(4):1057-66 [15746201.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7764-72 [15944279.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22596-605 [15817460.001]
  • [Cites] J Leukoc Biol. 2005 Sep;78(3):665-74 [16000387.001]
  • [Cites] Immunity. 2005 Oct;23(4):344-6 [16226499.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):953-64 [16322748.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):42794-800 [16263713.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):105-11 [16303292.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1074-82 [16619293.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Nat Immunol. 2006 Nov;7(11):1200-8 [16998493.001]
  • [Cites] Nat Immunol. 2006 Dec;7(12):1258-65 [17110942.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11432-40 [17145890.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):205-11 [17020928.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400 [17717638.001]
  • [Cites] Nat Med. 2008 Feb;14(2):176-80 [18204462.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3347-56 [18292560.001]
  • [Cites] Immunol Rev. 2008 Apr;222:155-61 [18364000.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4245-53 [18258799.001]
  • [Cites] Blood. 2008 Jul 1;112(1):64-72 [18434610.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):60-70 [19125020.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Annu Rev Immunol. 2009;27:451-83 [19105661.001]
  • [Cites] Nat Rev Immunol. 2009 Jul;9(7):465-79 [19521399.001]
  • (PMID = 21331365.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / CA-125 Antigen; 0 / Chemokine CCL3; 0 / Glycoproteins; 0 / Lectins, C-Type; 0 / Lipopolysaccharides; 0 / MUC16 protein, human; 0 / Mannose-Binding Lectins; 0 / Membrane Proteins; 0 / Mucins; 0 / Receptors, Cell Surface; 0 / mannose receptor; 0 / tumor-associated antigen 72; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC3038419
  •  go-up   go-down


Advertisement
4. Shinohara H, Niki M, Nomura E, Nishiguchi K, Okuzawa M, Chon Y, Hara H, Morita S, Tanigawa N: [A case of stage IV gastric cancer with multiple liver metastases and carcinomatous ascites responding to TS-1 for six months before progression]. Gan To Kagaku Ryoho; 2001 Jan;28(1):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric cancer with multiple liver metastases and carcinomatous ascites responding to TS-1 for six months before progression].
  • We report the case of a 72-year-old male with Stage IV gastric cancer accompanied by multiple liver metastases and carcinomatous ascites which responded to chemotherapy using TS-1.
  • Treatment of the patient with daily oral administration of 120 mg TS-1 for 4 weeks resulted in complete regression of the liver metastases and ascites, as well as a 35% reduction in the size of the primary lesion.
  • The patient received chemotherapy at our outpatient clinic for 10 months after the first treatment, after which he died of peritonitis carcinomatosa.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Ascitic Fluid / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Disease Progression. Drug Combinations. Humans. Male

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201387.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Fujitomi Y, Fujiyoshi K, Yasue K: [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis]. Gan To Kagaku Ryoho; 2000 Feb;27(2):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis].
  • One of the breast cancer patients introduced here suffered from recurrent carcinomatous pleurisy and the other from recurrent carcinomatous peritonitis.
  • The patient with recurrent carcinomatous pleurisy was a 47-year-old female with stage IIIa breast cancer.
  • Pleural exudate cytodiagnosis proved positive and the patient was diagnosed with carcinomatous peritonitis.
  • The patient with recurrent carcinomatous pleurisy was a 43-year-old female.
  • Following administration of 600 mg of UFT and 1,200 mg of MPA, the ascites decreased and improvement of the thickened peritoneum was noted.
  • It is anticipated that chemotherapy for carcinomatous pleurisy and carcinomatous peritonitis will contribute to an improvement in patients' QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Peritonitis / drug therapy. Pleurisy / drug therapy. Quality of Life
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Medroxyprogesterone Acetate / administration & dosage. Middle Aged. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700906.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; U3P01618RT / Fluorouracil; 1-UFT protocol; CAF protocol
  •  go-up   go-down


6. Inoue S, Kagawa M, Watanabe Y, Kusanishi H: [A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomatous peritonitis was suspected on abdominal CT scan and tumor markers were at high levels (CA125 10,827 U/ml, SLX 82 U/ml).
  • At laparotomy, massive ascites (3,000 ml), omental cakes and disseminated peritoneal tumors were revealed.
  • This low-dose CDDP intratumoral injection with CPT-11 may be effective for such omental tumors with carcinomatous peritonitis.
  • [MeSH-major] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Drug Therapy, Combination. Female. Humans. Injections, Intralesional. Injections, Intravenous. Middle Aged. Peritonitis / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484068.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Yuan ZP, Chen LJ, Wei YQ, Fan LY, Tang MH, Yang GL: [Nanoliposomal quercetin inhibits formation of malignant ascites of hepatocellular carcinoma]. Ai Zheng; 2006 Aug;25(8):941-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nanoliposomal quercetin inhibits formation of malignant ascites of hepatocellular carcinoma].
  • BACKGROUND & OBJECTIVE: Quercetin is a potential chemotherapeutic drug with many biological activities.
  • This study was to investigate the biodistribution of quercetin encapsulated by pegylated nanoliposomes and its therapeutic efficacy on the formation of carcinomatous ascites of hepatocellular carcinoma in mice.
  • The formation of malignant ascites, increase of body weight, survival time and peritoneal capillary permeability were assessed.
  • Apoptotic cells in ascites were detected by flow cytometry.
  • RESULTS: Nanoliposomal quercetin was a spherical particle with 25% drug content (W/W) and 130+/-20 nm in diameter.
  • Nanoliposome quercetin inhibited the formation of malignant ascites of hepatocellular carcinoma model in a dose-dependent manner.
  • Moreover, 100 mg/kg nanoliposomal quercetin significantly enhanced the apoptosis of cancer cells in ascites, inhibited the increase of body weight, reduced peritoneal capillary permeability and prolonged the survival time of tumor-bearing mice compared with PBS control.
  • CONCLUSION: Nanoliposomal quercetin can effectively accumulate in tumor tissues and inhibit the formation of malignant ascites, thus it might be used as a potential antitumor drug which deserves future study.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Ascites / prevention & control. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Quercetin / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Liposomes. Mice. Mice, Inbred BALB C. Nanoparticles. Neoplasm Transplantation. Polyethylene Glycols. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965672.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 9IKM0I5T1E / Quercetin
  •  go-up   go-down


8. Hara A, Tsunemi S, Yamamoto M, Izumi N, Iwamoto S: [Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1815-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites].
  • We used combination therapy of S-1 and Paclitaxel to treat gastric cancer complicated by carcinomatous ascites and assessed the clinical results.
  • The subjects were 8 patients who were gastric-cancer-ascites-positive, and they were treated by biweekly administration of S-1 orally, continuously for 2 weeks, and Paclitaxel on day 1 and day 8 of S-1 administration.
  • The results showed disappearance of the ascites on diagnostic images in 37.5% (3/8) and PR in 50% (4/8) in terms of the main gastric cancer focus.
  • We have reported this study because S-1+Paclitaxel therapy appears to be an important method of treating gastric cancer complicated by carcinomatous ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / complications. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Survival Rate. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030015.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Shindoh T, Matsuura N, Sugitachi A, Saitoh K: [A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites].
  • The carriers were prepared with fibrin hydrogel clots (FCs) and hemostatic gelatin powder (Gp) using an original technique, after which cis-platinum (CDDP) was loaded into the carriers.
  • The CDDP delivered in the incubation medium was mainly the protein-bound type, and the released CDDP inhibited the proliferation of AH-130 ascitic hepatoma.
  • To evaluate antineoplastic activities in vivo, we placed CDDP-loaded carriers into the abdominal cavities of AH-130 cancer-bearing rats.
  • Seven of 8 cancer-bearing animals treated with our CDDP-systems survived for more than 5 weeks, and evidence of malignancy completely disappeared.
  • All other rats died of cachexia with massive ascites and metastases within 2 weeks.
  • Thus, our newly devised system exhibited a sustained release of CDDP with possible antineoplastic efficacy in an experimental animal model with carcinomatous ascites.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ascites / drug therapy. Cisplatin / administration & dosage. Liver Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Delayed-Action Preparations. Drug Carriers. Hydrogels. In Vitro Techniques. Male. Rats

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484035.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Hydrogels; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Fukuda Y, Fujio N, Mayumi K, Ihara T, Terakura M, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case in which l-leucovorin/5-fluorouracil (l-LV/5-FU) combination therapy was remarkably effective for non-resectable advanced descending colon cancer with carcinomatous peritonitis.
  • Pathological examination of omental dissemination demonstrated moderately differentiated adenocarcinoma and cytology of ascites was class II.
  • There was no postoperative accumulation of carcinomatous ascites.
  • On abdominal computed tomography (CT), the primary lesion of the colon decreased 98% and there was no ascites found.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Quality of Life

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272595.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Toshimitsu H, Matoba K, Ozasa H, Shimizu R: [A resected case of effective treatment with TS-1 and CDDP for advanced gastric cancer with carcinomatous ascites]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of effective treatment with TS-1 and CDDP for advanced gastric cancer with carcinomatous ascites].
  • The 40-year-old woman initially complained of low abdominal pain, which was diagnosed as gastric cancer with metastasis of ovaries and carcinomatous ascites.
  • After 3 cycles of treatment, carcinomatous ascites disappeared and the ovarian lesion was reduced.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / etiology. Ovarian Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Cholecystectomy. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Hysterectomy. Ileum / surgery. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969035.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Ohdaira H, Suzuki Y, Tsutsui M, Iwasaki T, Arita M, Noro T, Kawasaki N, Ohara T, Yoshino K, Kuroda H, Kitajima M: Laparoscopy-assisted total gastrectomy for advanced gastric cancer with carcinomatous ascites after S1 plus cisplatin chemotherapy: a case report. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):e206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy-assisted total gastrectomy for advanced gastric cancer with carcinomatous ascites after S1 plus cisplatin chemotherapy: a case report.
  • A 29-year-old man with a type 4 tumor, in the lower third of the stomach, and carcinomatous ascites was diagnosed by aspiration cytology of the ascitic fluid.
  • The cancer lesion showed marked remission (partial response), and the ascites completely disappeared after the fourth course.
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Ascites / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Endoscopy, Gastrointestinal. Humans. Laparoscopy. Lymph Node Excision. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150404.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Sumii T, Funakoshi A, Ito T, Mizumoto K, Tanaka M, Migita Y, Sakai T, Shinozaki H, Yamaguchi H, Niyahara T, Muranaka T, Eriguchi N, Ueki T, Fukuoka Pancreatic Cancer Chemotherapy Group: [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Jul;30(7):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan.
  • Carcinomatous ascites and/or pleural effusion resulted in a poor prognosis (average survival 3.1 months).
  • These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Exanthema / chemically induced. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Survival Rate. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Nio Y, Iguchi C, Itakura M, Nishi T, Hashimoto K, Takeda H, Takamura M, Omori H, Sato Y, Koike M, Endo S: Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. Anticancer Res; 2009 Aug;29(8):3329-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction.
  • The placement of the PV stent was beneficial for administering chemotherapeutic agents and radiotherapy (RT) safely, and resulted in an improved response rate (RR) and survival.
  • RESULTS: The RR was 43% (3 complete (CR), 3 partial (PR), 3 stable disease (SD), and 5 progressive disease (PD)), and the mean survival times (MST) after the initiation of therapy or placement of the PV-stent were 12.6 and 9.5 months, respectively, while the 1-year survival rates were 54.5% and 35.1%, respectively.
  • In the 3 CR patients, 2 died of carcinomatous ascites 13 and 21 months later, and 1 is still disease free.
  • In the PR and SD patients, pain and PH-associated symptoms such as ascites and hyperglycemia were also improved.


15. Shimoyama S, Goshima F, Teshigahara O, Kasuya H, Kodera Y, Nakao A, Nishiyama Y: Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology; 2007 Jun;54(76):1038-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many genetically engineered viruses have been evaluated for their potential as a new therapeutic agent for cancer.
  • HF10, herpes simplex virus (HSV) type-1 clone, has remarkable anti-tumor effects, based on our previous research.
  • In vivo, BALB/c mice harboring carcinomatous peritonitis of CT26 cells were treated with HF10, paclitaxel or HF10 combined with paclitaxel.
  • RESULTS: HF10 is effective for peritoneal dissemination without ascites.
  • The combination of HF10 and paclitaxel prolonged survival of mice bearing carcinomatous dissemination of CT26 compared with the controls, HF10 alone and paclitaxel alone.
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / therapeutic use. Combined Modality Therapy. Mice. Mice, Inbred BALB C. Paclitaxel / therapeutic use

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629034.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Ohtani S, Shimizu Y, Sugiyama S, Miyade Y, Ninomiya M: [A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy]. Gan To Kagaku Ryoho; 2007 Jan;34(1):85-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
  • The patient was a 54-year-old male with peritoneal dissemination and carcinomatous ascites of advanced gastric cancer.
  • Although 4 months of temporary partial responses were obtained by a combination chemotherapy with TS-1 and DOC, retention of ascites appeared.
  • After 100 mg of CDDP had been administered, ascites almost disappeared.
  • These regimens seem to be effective in ambulant patients with advanced gastric cancer with peritoneal dissemination and carcinomatous ascites.
  • [MeSH-major] Ambulatory Care. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Ascitic Fluid / drug effects. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Quality of Life. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220677.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Shibata N, Eto TA, Hotokezaka M, Iwamura T, Chijiiwa K: [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
  • A 43-year-old woman who complained of abdominal fullness, appetite loss, and constipation was diagnosed as unresectable advanced schirrhous gastric cancer with left supra-clavicular lymph node metastases, massive ascites, rectal stenosis, and bilateral hydronephrosis due to peritoneal metastases.
  • After 3 courses, computed tomography showed markedly reduced supra-clavicular lymph node metastases and no ascites.
  • The biweekly paclitaxel and TS-1 chemotherapy may well be an effective treatment for advanced schirrhous gastric cancer with carcinomatous peritonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites. Constriction, Pathologic. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritonitis / etiology. Pyridines / administration & dosage. Rectal Diseases / etiology. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Okamoto N, Inaba K, Konno H: [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT scanning showed severe ascites and a low-density area 2 cm wide at the tail of the pancreas.
  • Ascitic cytology revealed adenocarcinoma and carcinomatous peritonitis due to pancreatic cancer.
  • Considering his general condition due to old age, the regimen for oral S-1 (80 mg/body/day) was set at 4 consecutive weeks of administration followed by a 2-week rest period.
  • There was no adverse drug reaction.
  • Six months later CT scanning showed that the ascites had disappeared and that the low-density area at the tail of the pancreas had become less obvious.
  • Twelve months since the therapy began: there still has been no adverse drug reaction and his QOL has been good.
  • This case suggests that S-1 is a safe and effective drug for very elderly patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged, 80 and over. Drug Combinations. Humans. Male. Peritoneum / pathology. Peritonitis / etiology. Quality of Life

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620815.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


19. Komiyama S, Nakamura M, Murakami I, Kuwabara Y, Kurahashi T, Tanaka K, Mikami M: A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet; 2008 Dec;278(6):565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
  • INTRODUCTION: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis.
  • No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer.
  • We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis.
  • After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease.
  • The toxicity of this drug was in the acceptable range.
  • It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritonitis / drug therapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Gynecol Obstet. 2009 Feb;279(2):271. Komiyama, Shin [corrected to Komiyama, Shin-ichi]
  • (PMID = 17576588.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Hatanaka F, Matsuo S, Aratake Y, Uchimura K, Yokota M, Sumii T, Iguchi H, Funakoshi A: [A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1]. Gan To Kagaku Ryoho; 2003 May;30(5):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1].
  • A 62-year-old man with carcinomatous ascites more than 5 years after early gastric cancer operation was admitted to our hospital because of suspected pancreatic cancer, and was diagnosed with a relapse of the gastric cancer.
  • At the end of 1 course a partial response of a decrease of tumor markers and ascites and improvement of QOL was achieved, and the patient was followed in the outpatient clinic.
  • The current case suggests that TS-1 may have a potent therapeutic efficacy in cases of gastric cancer relapse with carcinomatous ascites.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / therapeutic use. Peritonitis / drug therapy. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Ascites / drug therapy. Ascites / etiology. Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795106.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


21. Hirashima Y, Kitajima K, Sugi S, Kagawa K, Kumamoto T, Murakami K, Fujioka T, Noguchi T: [Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis]. Gan To Kagaku Ryoho; 2006 Apr;33(4):517-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal dissemination disappeared, liver metastasis almost disappeared after completion of two courses, and the therapeutic efficacy was rated as PR.
  • TS-1 and CDDP combination were given again, but an ileus resulted due to peritonitis carcinomatous.
  • The ileus disappeared after one week, liver metastatic lesions and ascites were improved after completion of one course, and therapeutic efficacy was rated as PR.
  • Paclitaxel can be expected to show good therapeutic efficacy and improve QOL of a peritonitis carcinomatosa patient with TS-1 resistant advanced gastric cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Liver Neoplasms / secondary. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Drug Resistance, Neoplasm. Gastrectomy. Humans. Lymph Node Excision. Male. Oxonic Acid / administration & dosage. Oxonic Acid / pharmacology. Pyridines / administration & dosage. Pyridines / pharmacology. Quality of Life. Tegafur / administration & dosage. Tegafur / pharmacology. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 0 / alpha-Fetoproteins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Yamagami W, Banno K, Kawaguchi M, Yanokura M, Kuwabara Y, Hirao N, Susumu N, Tsukazaki K, Aoki D: Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report. Chemotherapy; 2007;53(2):137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report.
  • BACKGROUND: The collagen gel droplet embedded drug sensitivity test (CD-DST) is a new anticancer drug sensitivity test that only requires a small number of cells.
  • CASE REPORT: The patient was a 70-year-old female with an ovarian tumor, pleural effusion, carcinomatous ascites and a chest wall tumor.
  • The histopathological diagnosis was adenocarcinoma, mature cystic teratoma with malignant transformation, stage IV.
  • Upon completion of 6 courses, no increases in carcinomatous ascites or recurrent lesions were evident, and the chest wall tumor had disappeared completely.
  • CONCLUSION: The CD-DST may be particularly useful for selecting preoperative chemotherapeutic drugs for patients with ovarian cancer in which the histological type of the primary tumor is unknown.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols. Collagen Type I. Drug Screening Assays, Antitumor. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Female. Gels. Humans. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17308380.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Collagen Type I; 0 / Gels; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Nukaya H, Hirashima N, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Sakakibara K, Sakamoto T, Kondo H: [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
  • We report an investigation of the therapeutic efficacy and safety of TS-1 single-agent therapy administered as first-line therapy in 23 cases of unresectable advanced gastric cancer treated at our institution.
  • In 1 patient, the carcinomatous ascites disappeared,and in 3 patients they decreased remarkably.
  • No significant differences were observed with regard to age (70 and over/under 70) or histological type (differentiated/undifferentiated).
  • The outpatient follow-up ratio(outpatient period/total treatment period) was high at 69.6%, meaning that first-line single-agent therapy with TS-1 is beneficial in terms not only of efficacy but also in maintaining quality of life.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Quality of Life. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement